Hap Trading, LLC Aurinia Pharmaceuticals Inc. Call Options Transaction History

Hap Trading, LLC

11 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2022 Aug 12, 2022	SELL	$8.95 - $12.8 $179,000 - $256,000	-20,000 Reduced 8.87%	205,500 $208,000
Q1 2022 May 12, 2022	SELL	$10.05 - $22.48 $234,165 - $523,784	-23,300 Reduced 9.36%	225,500 $356,000
Q4 2021 Feb 14, 2022	BUY	$17.78 - $33.08 $90,678 - $168,708	5,100 Added 2.09%	248,800 $1.99 Million
Q3 2021 Nov 10, 2021	BUY	$10.93 - $23.55 $114,765 - $247,275	10,500 Added 4.5%	243,700 $2.27 Million
Q2 2021 Aug 11, 2021	BUY	$10.0 - $14.52 $1.69 Million - $2.46 Million	169,300 Added 264.95%	233,200 $688,000
Q1 2021 May 14, 2021	SELL	$12.3 - $18.73 $2.08 Million - $3.16 Million	-168,800 Reduced 72.54%	63,900 $67,000
Q4 2020 Feb 16, 2021	BUY	$12.94 - $16.05 $244,566 - $303,345	18,900 Added 8.84%	232,700 $84,000
Q3 2020 Nov 13, 2020	BUY	$13.19 - $16.66 $2.68 Million - $3.39 Million	203,200 Added 1916.98%	213,800 $109,000
Q2 2020 Aug 10, 2020	SELL	$14.12 - $18.33 $282,400 - $366,599	-20,000 Reduced 65.36%	10,600 $31,000
Q1 2020 May 08, 2020	SELL	$11.34 - $21.46 $315,252 - $596,588	-27,800 Reduced 47.6%	30,600 $37,000
Q4 2019 Feb 11, 2020	BUY	$3.88 - $21.42 $226,592 - $1.25 Million	58,400 New	58,400 $485,000

209

58.7M

1.14M

1.51M

Ticker AUPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,892,000
Market Cap $1.15B
Description
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...

Get notified when there are updates to the investment portfolio of Hap Trading, LLC, based on Form 13F filings with the SEC.

Stay updated on Hap Trading, LLC with notifications on news.